Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Puma, but not noxa is essential for oligodendroglial cell death.
Shorter washout reduces MS relapse switching off natalizumab
Modulation of nitric oxide synthase by arginase and methylated arginines during the acute phase of experimental multiple sclerosis.
Early relapses, onset of progression, and late outcome in multiple sclerosis.
Dynamic imaging of individual remyelination profiles in multiple sclerosis.
Multiparametric MRI correlates of sensorimotor function in the spinal cord in multiple sclerosis.
The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
Acorda Therapeutics announces top line results of post-marketing commitment study exploring 5 mg dose of dalfampridine-ER
Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.
Imaging robust microglial activation after lipopolysaccharide administration in humans with PET.
Considering the influence of stimulation parameters on the effect of conventional and high-definition transcranial direct current stimulation.
Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
Predictors of quality of life among multiple sclerosis patients: a comprehensive analysis.
Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.
Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-beta-1b: a case report.
Ono to enter license agreements with Merck KGaA
Amiloride HCl
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis.
Liposarcoma concurrence in a multiple sclerosis patient treated with interferon-beta 1b.
Control of experimental autoimmune uveoretinitis by low dose T cell vaccination.
Pregnancy outcomes in female patients and partners of male patients in the teriflunomide clinical development program.
Pelvic Floor Muscle Training With and Without Electrical Stimulation in the Treatment of Lower Urinary Tract Symptoms in Women With Multiple Sclerosis.
Pages
« first
‹ previous
…
134
135
136
137
138
139
140
141
142
…
next ›
last »